1. Home
  2. EDD vs TSHA Comparison

EDD vs TSHA Comparison

Compare EDD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.52

Market Cap

345.5M

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.88

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
TSHA
Founded
2007
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
345.5M
1.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EDD
TSHA
Price
$5.52
$5.88
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$10.22
AVG Volume (30 Days)
254.3K
3.7M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
7.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,310,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.22
$1.05
52 Week High
$4.95
$6.02

Technical Indicators

Market Signals
Indicator
EDD
TSHA
Relative Strength Index (RSI) 51.39 63.88
Support Level $5.47 $5.37
Resistance Level $5.54 $5.96
Average True Range (ATR) 0.07 0.30
MACD -0.02 0.02
Stochastic Oscillator 26.09 88.79

Price Performance

Historical Comparison
EDD
TSHA

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: